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Altered growth factor expression during toxic proximal tubular
necrosis and regeneration
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Altered growth factor expression during proximal tubular necrosis and
regeneration. Growth factor expression was investigated during the
regenerative response after toxic proximal tubular necrosis. Therefore,
gentamicin was administered to rats to achieve an experimental model,
characterized by the appearance of segment-specific proximal tubular
necrosis, that is followed by a regenerative response leading to func-
tional and morphological recovery in a limited time. Four days after the
administration of the highest dose, serum creatinine rose to a mean
value of 5.8 mg/dl and returned to normal values ten days after the
treatment. The S1-S2 segment of the proximal tubules in the cortex
became clearly affected by severe toxic necrosis one day after the
treatment, while maximal necrosis was observed at days 2 to 4. Only
minor injuries were noticed in the other renal compartments. The
proliferative response started in the interstitial cells first. The major
proliferative wave was localized in the convoluted part of the proximal
tubules at days 6 to 8, although proliferation was also prominent among
non-proximal tubular cells. A profound interstitial infiltration of leuko-
cytes, including macrophages and T lymphocytes, was observed. Ten
days after the treatment the functional and morphological recovery
were completed. Slot blot hybridization revealed a decreased EGF and
IGF-I mRNA expression from the start of the observation period. While
IGF-I mRNA had regained its normal expression at day 10, EGF
mRNA was still below control levels. The PDGF-B transcript became
more abundant towards the end of our observations. No major changes
in the expression of TGF-a, TGF-3l and c-fos were detected. Renal
EGF-immunoreactivity disappeared from the luminal plasma mem-
brane of the distal tubular cells analogous to the results obtained at the
messenger level. However, EGF-staining was lost in the cortex first,
hence a topographical association between the loss of EGF-immunore-
activity in the distal tubules and the observed necrotic lesions in the
proximal tubules was found. Immunoreactive EGF was never observed
in proximal tubular cells from normal, injured or regenerating rat
kidneys. We conclude that in this experimental rat model, EGF and
IGF-I mRNA expression is decreased during the regenerative response
upon severe toxic tubular necrosis. No evidence for a participation of
EGF or IGF-I of renal origin in the recovery of the kidney is found.
Acute renal failure caused by toxic substances evokes a
proliferative response in the damaged tubules and often also in
the interstitium [1]. Although the mechanisms of injury that lead
to cell death and the tubular cells that are predominantly
affected can be very diverse [2], necrotic tubular cells are
thought to be replaced by the remaining cells, which, from their
resting state (G0), re-enter the cell cycle and proceed through
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DNA-replication (S) into mitosis (M). Currently, the signals
that activate this transition are not well understood [3]. How-
ever, one can presume that, in order to restore the complete
tissue architecture and kidney function, control of this process
has to be very precise.
There is increasing evidence that polypeptide growth factors
such as epidermal growth factor (EGF), the transforming
growth factors (TGF-a and TGF-/3), the insulin-like growth
factors (IGF-I and IGF-II), the fibroblast growth factors (aFGF
and bFGF), plateled-derived growth factor (PDGF) and proto-
oncogenes like c-fos could be involved in the regenerative
processes [4—6]. Indeed, tubular cells as well as interstitial cells
can produce and/or secrete several of these factors, and they
also bear receptors for them [7]. Hence, the local release of
growth factors may modulate the repair process in an autocrine,
paracrine, juxtacrine or endocrine manner [8—10]. Our current
knowledge about growth factor activities is mainly gathered by
in vitro research [11]. However, substantially less is known
about their physiological relevance in vivo. Unravelling the
expression pattern of these factors during the regenerative
process can provide new insights in their roles in the restoration
of the structural and functional integrity of the kidney [12, 13].
In an experimental rat model different doses of gentamicin
were used to induce varying degrees of proximal tubular
necrosis, mainly confined to the convoluted part (Sl-S2 seg-
ments). Two experimental designs were used in this study.
Since in a preliminary experiment serum creatinine values did
not rise, necrotic lesions were absent despite the presence of
cellular proliferation, and the EGF mRNA level remained
unchanged after administration of 140 mg/kg gentamicin, a
substantially higher dose of gentamicin was used in the present
study to induce regenerative events in a limited period of time
in response to extensive segment-specific tubular necrosis. A
second experimental design was inspired by the description of a
redistribution of renal EGF after gentamicin or amikacin ad-
ministration to rats [14, 15].
Growth factor expression was evaluated concomitantly with
the damage and subsequent regeneration, which we investi-
gated in the different histological compartments for a period of
ten days. As interstitial infiltration is a recognized feature of
nephrotoxic injury [1, 2, 16] that was also observed in previous
studies of our laboratory [17, 18], and because of its potential
importance in tissue remodeling, the identity of the interstitial
infiltrating cells was also determined and their presence was
quantified. In addition to the mRNA expression of renal EGF,
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TGF-, TGF-pl, IGF-I, PDGF-B and c-fos, the histological
distribution of EGF of renal origin was investigated immuno-
histochemically.
Methods
Animal treatment
Two different dosage schedules were used, The treatment of
group B is based on previous work in our laboratory [17, 18] and
on preliminary experiments in our laboratory. For group A the
same experimental design as previously described was used
[19].
Group A. Male Sprague-Dawley rats (190 to 210 g) were s.c.
injected twice a day (9:00 a.m.; 6:00 p.m.) with 10 mg/kg
gentamicin during 10 days.
Group B. Female Wistar rats (225 to 250 g) received a daily
dose of 400 mg/kg gentamicin (40 mg/mI) in three subcutaneous
injections (8:00 a.m.; 4:00 p.m.; 12:00 p.m.) during two consec-
utive days. In addition, four experimental animals and four
control animals did not receive the full treatment and were
sacrificed after only one day treatment (further referred to as
the day —1 sample), enabling the observation of early effects.
Control rats for the two groups received equal volumes of
0.9% NaCJ under the same regimen. Animals had free access to
rodent standard chow and tap water. One hour before sacrifice,
200 pCi 3H-thymidine (NEN, Du Pont de Nemours, Wilming-
ton, Delaware, USA) was injected intraperitoneally to evaluate
cellular proliferation. The rats from group A were sacrificed by
cervical fracture 24 hours after receiving their last injection.
The rats from group B were killed between eight hours (that is,
day —1 for those rats treated during one day, day 0 for the rats
that completed the treatment of two days) and ten days after the
last injection.
Sample collection
Serum samples were taken at the time of sacrifice. After
exposure of the abdominal cavity, kidneys were decapsulated
and quickly removed. The right kidney and a part of the liver
were snap-frozen in liquid nitrogen and stored at —80°C, until
DNA- and RNA-extraction procedures were performed. The
left kidney was cut into 1 mm thick transverse slices and
processed for further histological analysis using different fixa-
tion procedures. A cortex sample from the left kidney was
weighed and stored at —20°C for determination of the genta-
micin content.
Serum creatinine
Creatinine values in the serum were measured in duplicate by
a Jaffé-modified colorimetric reaction (Creatinine Merckotest,
Diagnostica Merck, Darmstadt, Germany).
Gentamicin in the kidney cortex
Gentamicin was extracted from cortex samples as previously
described [20]. The cortical accumulation of gentamicin [21]
was measured with a commercial RIA-kit (Gammacoat [125I]
Gentamicin Radioimmwioassay kit, Baxter Healthcare Corp.,
Cambridge, Massachusetts, USA).
Light microscopy and histoautoradiography
Tissue slices (1.5 mm thick) were immersed during four hours
in Dubosq-Brazil fixative at room temperature, rinsed in 70%
ethanol and embedded in low melting point paraffin (BDH
Chemical Ltd., Poole, UK). Sections (4 pin) were cut and
mounted on chrome(III)potassium-sulfate-gelatin coated micro-
scope slides, rehydrated and covered with autoradiographic
emulsion (Kodak NTB 2 from Technomara AG, Wallisellen,
Germany). After exposure for two to seven weeks at 4°C, slides
were developed. Before staining with periodic acid/Schiff re-
agent, silver grains were stabilized by gold latensification.
Nuclei were counterstained with hematoxylin. Neighboring
sections were stained with hematoxylin-eosine only.
Immunohistochemical stainings
Staining procedures were essentially as previously described
[22]. For EGF, tissue slices (1.5 mm thick) were fixed on
melting ice during 90 minutes in 4% formaldehyde (BDH
Chemical Ltd.) buffered with 0.1 M Na-cacodylate pH 7.4
containing 1% CaC12. After washing, tissue was embedded in
low melting point paraffin (BDH Chemical Ltd.). Sections (4
/xm) were mounted on poly-L-lysine coated microscope slides
and rehydrated. After equilibration in TSB (10 mrs Tris-HCI pH
7.6; 0.9% NaCI; 0.1% Triton X-100 and 0.004% merthiolate) and
incubation with normal goat serum (1/5) during 20 minutes,
rabbit anti-mouse EGF antiserum (1/5000) (Amersham Interna-
tional plc., Amersham, UK) was applied for overnight incuba-
tion. After washing, sections were treated with biotinylated
goat anti-mouse antiserum, followed by the addition of the
avidine-biotine peroxidase complex (Vector Laboratories Inc.,
Burlingame, Vermont, USA). Peroxidase staining was per-
formed with 3-amino-9-ethylcarbazole as a substrate. No stain-
ing was observed after applying antiserum that was previously
incubated for 24 hours with a dilution series of mouse submax-
illary gland EGF (Gibco Life Technologies, Inc., New York,
New York, USA) from 18 ng/ml to 18 jg/ml.
Tissue slices for leukocyte stainings were fixed the same as
for EGF staining. Sections (4 pm) were mounted on poly-L-
lysine coated microscope slides and treated for five minutes
with 0.003% trypsin III (Sigma Chemical Co., St. Louis,
Missouri, USA) in 10 m'vi Tris-HC1 buffer pH 7.3. After washing
in TSB and treatment with normal horse serum (1/5), the
sections were incubated overnight with the primary antibodies
OXl (1/6000), OX8 (1/4000) or 0X41 (1/1600) (Serotec, Oxford,
UK). The OX1 Mab recognizes the rat leukocyte common
antigen, which is present on all marrow-derived leukocytes,
that is, thymocytes, bone marrow cells, peripheral lymphocytes
and macrophages [23]. OX8 reacts with T cytotoxic/suppressor
cells (CD8) and natural killer cells [24]. OX41 is specific for
macrophages, polymorphic nuclear cells and dendritic cells,
expressing the CDl1 antigen [25]. The appropriate dilutions
were determined in preliminary experiments. Endogeneous
peroxidase activity was destroyed by immersion in methanol,
followed by 30 minutes in 0.03% hydrogen peroxide. After
washing, biotinylated horse anti-mouse serum was added for 30
minutes. Further staining was the same as for EGF.
Leukocyte cells were quantified in six microscopic fields for
each animal by means of an image analyzer system (Vicom
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Systems Inc., USA), and positive areas were expressed as a
percentage of each randomly selected field.
3H-thymidine incorporation
Genomic DNA was isolated from the lower part of the right
kidney and from the liver, the latter to check the organ
specificity of cell proliferation. Briefly, tissue was homogenized
in 150 mM NaClIlOO m EDTA pH 8.0 in a Dounce homoge-
nizer. Cells were lysed by the addition of 0.2 volumes 10% SDS
and NaClO4 to a final concentration of 1 M. Proteins were
phenol/chloroform-extracted and the genomic DNA was etha-
nol-precipitated. The resulting DNA slurry was dissolved in 10
ifiM Tris-HC1/l mr'.i EDTA pH 8.0. Duplicate samples of the
DNA extract were counted in Aqualuma scintillation fluid
(Lumac by., Schaesberg, The Netherlands) in a scintillation
counter (Tri-Carb 2660 from N.Y. Canberra Packard, Brussels,
Belgium). Counting efficiency was estimated by an external
standard in combination with the sample quenching curves. To
correct the counting data for sample DNA content the concen-
tration was determined by a colorimetric assay based on the
diphenylamine reaction [26]. Serum- and acid-soluble tissue
radioactivity was counted to assure consistent intraperitoneal
absorption and tissue distribution of the radioactive label.
Unreliable incorporation results (as indicated by the absence of
a single labeled nucleus and the extreme low specific activity of
the extracted DNA) from animals with an insufficient intraperi-
toneal absorption of the label (serum radioactivity less than
1250 dpml.d) were excluded.
Morphological and histoautoradiographic analyses
Tissue injury was evaluated in the different renal tubular
compartments (proximal tubules of cortex (S1-S2) and outer
stripe of the outer medulla (S3), non-proximal tubules of cortex
and outer stripe of the outer medulla) [271, based on following
criteria: normal/undamaged, damaged cells, cellular necrosis,
and completely necrotic. Damage included the presence of
extensive vacuolization and the intracellular accumulation of
PAS-positive inclusions. Even in regenerative conditions, dis-
tinction between proximal and non-proximal tubules could be
made by the absence of a clearly recognizable intercellular
delineation and eventually by the presence of a brush border in
the proximal tubules. Non-proximal tubules were identified by
the presence of a clearly recognizable intercellular delineation
and by the presence of PAS-positive stripes perpendicularly
orientated near the basal cell surface [28].
Labeled nuclei per mm2 were counted in 20 microscopic
fields in the cortex and the outer stripe of the outer medulla at
a magnification of 312x, with a distinction made between
proximal tubular cells, non-proximal tubular cells and intersti-
tial cells.
Northern and slot blot analysis
Total RNA was extracted from the upper part of the right
kidney using a guanidiniumthiocyanate procedure [29]. After
one round of oligo-dT-cellulose chromatography [30], yield and
purity of the poly-A+ fraction were determined spectrophoto-
metrically. Probe specificity was assured by means of Northern
blot analysis. The following cDNA inserts were used as a
probe: a 3.3 kb Eco RI cDNA insert, containing the partial
coding sequence of the rat prepro-EGF mRNA [31]; the 0.5 kb
Eco RI cDNA insert of prigfl-l, containing the entire coding
sequence and parts of the 3' and 5' untranslated region of the rat
IGF-I mRNA [321; the 2.3 kb Eco RI cDNA insert ofprTGF02,
containing the partial coding sequence and part of the 5'
untranslated region of the rat preproTGF-a mRNA [33, 34]; the
1.0kb Eco RI cDNA insert of pf3as, containing the entire coding
sequence of human TGF-f31 mRNA [35]; the 2.2 kb Eco RI
cDNA insert of pc-fos(rat)- 1, containing the entire coding
sequence of rat c-fos rnRNA [36]; the 1.9 kb Barn HI cDNA
insert of pMVW-2, containing the entire coding sequence and
parts of the 3' and 5' untranslated region of human PDGF-B [371
and the 0.3 kb Pst I cDNA insert of pSPf3act72, containing part
of the 3' untranslated region of rat /3-actin. Poly-A+ samples (5
g) were fractionated electrophoretically through formalde-
hyde-1.2% agarose gels and fixed on positively charged nylon
membranes (Hybond-N+ from Amersham International plc.)
by alkaline vacuum transfer (Vacugene XL blotting unit from
Pharmacia LKB Biotechnology, Uppsala, Sweden). For quan-
tification purposes equal amounts of poly-A+ samples were slot
blotted (Biodot SF microfiltration unit from Bio-Rad Laborato-
ries, Richmond, Virginia, USA).
After amplification of the plasmids containing the inserts,
cDNA probes were prepared according to standard procedures
[381, and 32P-labeled by random primed DNA synthesis [39]
(Multipnme DNA labeling kit from Amersham International
plc.) to a specific activity of 0.5 to 1. io cpm/jg DNA. After
overnight prehybridization at 42°C in 5 X SSC, 0.1% SDS, 5 x
Denhardt's solution, 50 m sodium phosphate pH 7.0, 0.25
mg/mi denatured sonicated salmon sperm DNA and 50% deion-
ized formamide, the labeled probe was added to hybridize for 24
hours under the same conditions. Stringency of the washes for
each probe were determined in preliminary experiments. Fi-
nally, blots were exposed to preflashed Fuji HRG autoradio-
graphic film at —80°C in a film cassette with two intensifying
screens. To quantify the growth factor response, hybridization
signals of the slot blots were densitometrically scanned and
integrated by a digital imaging system (Datacopy GS + scanner
and MacIntosh IIcx personal computer, Imagecopy and Scan
Analysis software). Variations in isolation, application or trans-
fer of the poly-A+ RNA were accounted for by reprobing the
blots with a cDNA probe for rat /3-actin. The expression of
13-actin mRNA was inversely correlated with the amount of
RNA eluting from the oligo-dT-cellulose columns (Spearmans
rank correlation coefficient: —0.607; P < 0.0001), indicating
that variation in f3-actin expression was predominantly an
artifact of a variable poly-A+ sample content after poly-A+
enrichment.
Statistics
Results are expressed as the mean SEM. Differences
between the control group and the experimental groups were
evaluated using the Mann Whitney U test. P values of 0.05 or
less were considered as significant.
Results
Serum creatinine values
In group A, serum creatinine values were not elevated (data
not shown). In group B the rise of the serum creatinine values,
starting at day 0, gave evidence for an early decrease in
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glomerular filtration rate, whereas control rats maintained nor-
mal values throughout the experimental period (Fig. 1). Serum
creatinine values from the treated rats peaked at day 4 (5.8
0.6 mg/dl) and fell to nearly normal values at day 10.
Gentamicin accumulation in kidney cortex
After two days of treatment gentamicin in the kidney cortex
of group B had reached a maximal concentration and decreased
quickly thereafter (Fig. 1).
Morphological studies on tissue injury
By light microscopy, no clear morphological damage was
observed in group A, except for the presence of some PAS-
positive inclusions in proximal convoluted tubular cells (data
not shown).
It clearly appeared from our morphological data from group B
that even at high doses the segment specificity of the nephro-
toxic action of gentamicin was preserved (Fig. 2). In the cortex
the majority of the proximal tubular cells (S1-S2) were injured
at day 0. In the next days, most of the proximal tubules became
completely necrotic. The denuded basement membrane became
gradually covered with flattened, labeled epithelial cells at day
6 (Fig. 3), and by day 10 tubular morphology was restored in
most animals. By contrast, minor lesions were noticed in the
other tubular segments: necrotic proximal tubules in the outer
stripe of the outer medulla (S3) were exceptional, injuries being
mostly confined to shedding of the brush border and the
accumulation of PAS-positive granules in the cytoplasm. Al-
though some disrupted cells were present in the non-proximal
tubules from both cortex and outer stripe of the outer medulla,
no necrotic areas were observed.
Proliferative response
In group B the renal proliferative response started at day 0
(Fig. 4A). Maximal proliferation occurred at day 6. The incor-
poration in liver DNA was not significantly elevated at any time
(Fig. 4B).
Labeling indices for individual cell types were calculated
from histoautoradiographical data. Cellular proliferation in
group B reflected the incorporation data of the renal DNA
extract. In the histological compartments essentially three
proliferative waves were observed (Fig. 5). First, the number of
labeled interstitial cells from cortex and outer stripe of the outer
medulla rose very early (day 0). At day 6, interstitial prolifera-
tion faded away but at day 10 proliferative activity was still
present. Second, proliferation in non-proximal tubular cells and
in the proximal tubular cells from the outer stripe of the outer
medulla started at day 2, and decreased slowly towards day 10,
not yet being normalized at that time. Third, the major prolif-
erative wave, localized in the proximal tubular cells from the
cortex (S1-S2), started only at day 4 and peaked at day 6.
Glomerular cell proliferation was not significantly elevated
(data not shown).
Interstitial infiltration
Since a profound interstitial proliferation was present in
group B, the identity of the interstitial infiltrates was investi-
gated immunohistochemically. In normal interstitium, 0.3% of
the investigated area was OX1-positive (Fig. 6). In the experi-
mental rats, a massive leukocyte infiltration was present
throughout the observation period, being maximal at day 2
(12.7%). T suppressor/cytotoxic cells, as revealed by the 0X8
Mab, covered 0.2% of the investigated area in control rats. In
the gentamicin-treated animals, the 0X8-positive cells infil-
trated from day 0 onward. While 0X41-positive cells (macro-
phages/granulocytes) were occasionally observed in control
rats (0.02%), a transient infiltration was prominent in the
experimental rats, peaking at day 4 (1.6%).
Growth factor expression
By means of Northern blot hybridization, the mRNA expres-
sion of several polypeptide growth factors was investigated in
the kidney (Fig. 7). An intense 5.0 kb band revealed the
abundant presence of the preproEGF transcript in the kidney,
as has been reported by others [40—43]. For IGF-I, three distinct
bands of 7.0, 1.6 and 1.1 to 0.6kb were observed. This profile
is in accordance with previous results [321 and since IGF-I is
encoded by a single copy gene probably the consequence of
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alternative splicing of the IGF-I mRNA [44, 45]. A very weak
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human TGF-/31 probe yielded a 2.5 kb band of moderate
intensity, which matches the transcript of the rat's equivalent
[47—50]. The presence of the PDGF-B in the kidney was
confirmed by the presence of a single 3.8 kb transcript [37, 51,
52]. Finally, the presence of the 2.1 kb c-fos transcript in the
normal rat kidney was very low, which is in agreement with
previous reports [36, 53].
In group B, EGF mRNA fell to nearly undetectable levels at
day 1 and remained low thereafter (Fig. 8). However, the level
of the transcript was increasing again at the end of the obser-
vation period (day 10) as compared to day 8 (P < 0.05).
Analogous to EGF, IGF-I mRNA level was also decreased,
although not as dramatically as for EGF and, by contrast, it was
completely normalized at day 10. The PDGF-B transcript
increased significantly towards the end of the observation
period. No consistent changes were observed in the level of the
other transcripts examined, that is, TGF-a, TGF-pl and c-fos.
All values were standardized against /3-actin mRNA expres-
sion.
EGF immunoreactivity
Immunohistochemical staining revealed that EGF expression
in normal kidney was confined to the thick ascending limb of
Fig. 5. Labeling index in different renal
compartments from group B. Each bar
represents the mean SEM. * P < 0.05
versus the group of six control rats (three
each from days — I and 10).
Henle (TAL) and the distal convoluted tubule (DCT) (Fig. 9).
Staining was most prominent at the apical cell surface. No
staining for EGF was observed in the macula densa. In group B,
immunoreactive EGF decreased after I day of gentamicin
administration, and did not reappear until days 8 to 10, in
analogy to the disappearance of the EGF mRNA. However, the
initial loss was confined to the distal tubules from cortex, that
is, the area in which the severe proximal tubular necrosis was
localized. Thereafter, EGF expression was also lost in the distal
tubular cells of the outer stripe of the outer medulla. EGF
staining started to reappear at day 10 similar to the Northern
results. Immunoreactive EGF was never observed in proximal
tubular cells. In group A neither a loss of EGF immunoreactiv-
ity nor its appearance in proximal tubular cells were observed.
Discussion
The possible involvement of several growth factors in the
triggering and maintenance of the observed proliferation events
was investigated at the mRNA level. A strong decrease in the
expression of EGF was observed during the injury and the
recovery phase in group B, but not in group A, both at the
messenger and the protein levels. This illustrates that substan-
tial injury is a prerequisite to affect the expression levels of
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OX1, pan-leukocytes ischemia and cisplatin administration [40, 411. A direct interac-
tion with gentamicin as the cause of this decline is therefore
14 unlikely. Whether the concomittant decrease of EGF and its
12 messenger has to be ascribed to a decline in transcription rate
and/or a decreased mRNA stability remains to be determined. It
10 is also not clear what causes the topographical association
between the initial disappearance of EGF from the distal
8 tubular segments and the adjacent site of proximal tubular
6 injury. This phenomenon was also observed in preliminary
experiments using mercurychioride as an inducer of segment-
4 specific toxic lesions in the proximal straight tubules of the
outer stripe of the outer medulla (unpublished observations).2 The question remains whether the decreased EGF is the
0 result of damage to the distal tubular cells, whether it is due to
Day: —1 0 1 2 4 6 8 10 controls functional alterations in the distal nephron, or whether it is part
N 4 4 4 4 4 4 4 4 23 of a specific control mechanism.
The first possibility is unlikely since clear distal tubular
necrosis was absent; the small number of necrotic cells in the
B 0X8, T suppressor-cytotoxic cells distal tubules that possibly escaped our observations cannot
explain the virtual disappearance of EGF from the entire length
of the distal tubule. Furthermore, no morphological damage hadCe
occurred to this part of the nephron when EGF started to
disappear.
As for the possible role of a local decrease in EGF concen-
tration acting as a specific regulatory signal during kidney
regeneration, there are a number of indications which support
this hypothesis. EGF can transiently arrest A431 human epi-
dermoid carcinoma cells (that bear EGF receptors abundantly)
in their G2-phase [54—56]. Furthermore, EGF seems to inhibit
organ growth in neonatal rats [57, 58]. It is noteworthy in this
*
regard that EGF mRNA cannot be detected in neonatal mice
until four days after gestation [59], nor can it in human fetalDay: —1 0 1 2 4 6 8 10 controls tissues [60]. Also, EGF mRNA is decreased in congenitalN= 4 4 4 4 4 4 4 4 24 polycystic kidneys in mce [42, 61]. Nevertheless, the number
of reports in this context are few in comparison to the number
C 0X41, macrophages + granulocytes of descriptions of EGF as a stimulator of mitosis [62—67].On the contrary, several facts make it difficult to understand
how such a mitogenic activity could be exerted during proximal
tubular regeneration. We could not demonstrate an autocrine
3 role for renal EGF, being unable to detect any EGF immuno-
reactivity in proximal tubular cells, neither after mild, nor after
severe proximal tubular injury. Perhaps, as Laurent and co-
2 workers suggest, the redistribution of EGF immunoreactivity
which they have observed using an immunogold technique [14,
15], indicates an increased binding of EGF to its receptor.
1 However, this needs confirmation since it is still not clear how
the renal EGF, localized at the luminal plasma membrane of
distal tubular cells could bind to the EGF receptors of the
0 proximal tubular cells that are exclusively localized at theirbasolateral membranes [68]. Although transcytosis of EGF inDay: —1 0 1 2 4 6 8 10 controlsN= 4 4 4 4 4 4 4 4 24 cultured renal epithelial cells has been described, it was di-
rected from the basolateral towards the luminal surface [69].
Immunoreactivity Despite the fact that no EGF receptor analysis was performed
Fig. 6. Positive fractional area of the immunoreactive infiltrating cells, in the present study, the relevance of disruption of the tight
Each bar represents the mean SEM. * P < 0.05 versus the group of 24 junctions and loss of tubular cell polarity, which would allow
control rats, distal tubular EGF to reach its receptor, could be questioned,
since distal tubular EGF is virtually absent in our model when
EGF, and of IGF-I. A similar loss of EGF mRNA expression, its mitogenic properties would be most appropriate.
together with a decline in urinary EGF output, has been Nevertheless, other data indicate that EGF does have a
observed in other models of acute renal failure, that is, after beneficial effect on renal regeneration. Humes and co-workers
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Fig. 7. Northern hybridization of different
mRNA transcripts detected in normal
adult rat kidney, except for c-fos (group B
after 2 days treatment). A. EGF mRNA:
one transcript of 5.0 kb. B. IGF-I mRNA:
three transcripts of 7.0, 1.6 and 1.1 to 0.7
kb. C. PDGF-B mRNA: one transcript of
3.8 kb, D. TGF-a mRNA: one transcript of
4.8 kb. E. TGF-/31 mRNA: one transcript
of 2.5 kb. F. c-fos mRNA: one transcript
of 2.2 kb. G. /3-actin mRNA: one
transcript of 2.1 kb.
have reported a hastened recovery from ischemic and mercury
chloride-induced acute renal failure after i.p. administration of
EGF [70, 71]. Together with the higher EGF receptor density
previously reported [72], this suggests that in these circum-
stances circulating rather than renal EGF could be important.
On the other hand, also TGF-a, which is able to activate the
EGF receptor [73], is shown to accelerate renal repair following
ischemic injury [74]. However, the same enigma occurs as for
renal EGF, since renal TGF-a has been localized in the collect-
ing duct [75], that is, downstream from the site of injury.
Furthermore, TGF-a mRNA remained relatively constant in
our model.
Alternatively, EGF of renal origin might act at the lower
urinary tract [43] in analogy to the activity of salivary gland
EGF on the gastrointestinal epithelia [76], the more since it has
been demonstrated that the renal EGF precursor can be cleaved
by a membrane bound aprotinin-inhibitable proteinase [77, 78]
and several kidney derived EGF-like peptides can be detected
in the urine [79]. Furthermore, it is intriguing that the EGF
precursor molecule contains several EGF-like domains in addi-
tion to the mature EGF [80, 81]. The homology with the
LDL-receptor further suggests alternative functions, unrelated
to cellular proliferation [82].
Several investigators have reported the collecting duct to be
the major site of renal IGF-I expression [83—86]. The presently
observed decrease in IGF-I mRNA content is not as dramatic as
for EGF mRNA. Again, it is difficult to reconcile such a
response with a role for renal IGF-I as a proliferation promoting
substance involved in the regeneration of the kidney. Since
there is evidence for the existence of an intrarenal EGF-IGF-I
axis [87], the presently observed decline in preprolGF-I mRNA
might be the result of a decreased paracrine stimulation of
IGF-I mRNA production by the distal tubular EGF. However,
this cannot explain the return to normal levels of IGF-I mRNA
while renal EGF is still far below its normal level of expression.
In the present study, PDGF-B mRNA was the only growth
factor that was significantly elevated. In addition to its role in
the proliferation of fibroblasts and other cells of mesenchymal
origin [88], PDGF elicits chemotactic responses in fibroblasts
and smooth muscle cells and stimulates the deposition of
collagen [89]. Some studies have suggested that PDGF and
PDGF receptors may mediate destructive proliferative pro-
cesses within tissue sites, including the kidney [90—92]. The
tubulointerstitial fibrotic lesions that sometimes develop after
severe tubular injuries [93] therefore may be foretold by the
increased abundance of the PDGF-B transcript at the end of our
experiment. Several studies have also demonstrated an induc-
tion of PDGF-B mRNA by TGF-13 [94] and vice versa, TGF-/3
was induced in fibroblasts and infiltrating macrophages in
PDGF-treated wounds [89]. The similar expression patterns of
PDGF-B mRNA and TGF-/31 mRNA may be a further confir-
mation of this relationship, although TGF-/31 mRNA level was
not significantly altered.
No consistent variation in the mRNA expression of TGF-a,
TGF-/3l and c-fos was observed. However, this does not
exclude a possible role for these factors in the regenerative
events since posttranslational mechanisms such as receptor
affinity changes, alterations in signal transduction or activation
of latent forms are not always accompanied with a modified
mRNA content. Also, since RNA extracted from the whole
kidney was used, it was impossible to detect any local differ-
ences in expression that may have occurred for these factors.
The broad interval in which the different renal ceiltypes re-
entered the cell cycle made it difficult to detect significant
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variations for the c-fos mRNA, considering the very rapid and
transient activation of the gene [95]. Furthermore, it has been
suggested that c-fos induction in Swiss 3T3 cells is not obliga-
tory for the mitogenic response for these cells [96].
The interstitial infiltration of leukocytes was massive, persis-
tent and appeared before the onset of distinct tubular necrosis.
Whether this observation plays a primary or a secondary role in
renal injury is not known. However, mononuclear cells and
macrophages can secrete soluble factors that can stimulate the
resident fibroblasts in the renal interstitium [97]. The early
infiltration may therefore eventually lead to interstitial fibrosis
and progressive deterioration of renal function associated with
chronic renal disease. The mechanism underlying the develop-
ment of this cellular infiltrate is not clear. Since T cell infiltra-
tion was a prominent feature of this phenomenon, cell-mediated
mechanisms may have contributed to it. Since renal tubular
cells can produce proinflammatory cytokines such as TNFa,
and can act as antigen presenting cells by expressing the MHC
class II complex, it is possible that these cells have participated
in the immune response [98]. Alternatively, the interstitial
infiltration could be secondary to early cellular damage due to
the lysosomal gentamicin overload [17, 21]. This attractive
hypothesis unifies several models of tubulointerstitial injury,
such as severe toxic and ischemic nephropathy, and protein-
usia-induced tubulointerstitial nephritis, all characterized by
tubular epithelial cell injury and disruption being the final
common pathway [99—101]. The outcome largely depends on
the severity and reversibility of the initial insult.
In summary, we have chronologically characterized a model
in which gentamicin-induced toxic segment-specific tubular
injury was followed by regeneration resulting in a complete
recovery. In this model an early decreased preproEGF mRNA
content, accompanied by the disappearance of renal EGF at the
apical surface of the distal tubular cells, was seen simulta-
neously with the induction of distinct renal injury. Further-
more, distal tubular cells adjacent to the necrotic proximal
tubules in the cortex have lost their EGF expression first, while
immunoreactive EGF was never observed in proximal tubular
cells. IGF-I mRNA decreased also but regained its normal
expression after restoration of normal tissue morphology. The
150%
100%
50%
EGF, mRNA
**
IGF-I mRNA150%
100%
50%
**
0% 0%
Day: —1 0 1 2 4 6 8 10 controls Day: —1 0 1 2 4 6 8 10 controlsN= 44424444 23 N= 44424444 23
TGF-a mRNA
2 4 6 8 10 controls Day:—1 0 142333 21 N= 444
Fig. 8. Slot blot densitometric analysis of the
growth factor mRNA from group B. Each bar
represents the mean SEM as a percentage of
the mean from the control animals. Values are
corrected for variations in isolation, transfer,
or application of the mRNA by normalization
versus the 13-actin mRNA content. * P < 0.05
2 4 6 8 10 controls versus the control group. ** P < 0.01 versus2 4 4 4 4 23 the control group.
1276 Verstrepen et a!: Growth factor expression during regeneration
Fig. 9. Photomicrographs of the
immunoreactive renal EGF. A. Control
animal from group B: uniform expression
pattern throughout outer stripe of the outer
medulla and cortex (magnifiction x 45).
B. Animal from group B one day after the
treatment (day 0): EGF immunoreactivity
has disappeared from the cortex
(magnification x 45). C. Animal from
group B four days after the treatment (day
4): EGF immunoreactivity has completely
disappeared (magnification x 45). D. Detail
from a control animal from group B. EGF
immunoreactivity is confined to the TAL
and the distal convoluted tubules. Staining
is most prominent at the apical cell
surface. No immunoreactivity was
observed at the macula densa (arrowhead)
(magnification x 180). E. Animal from
group A 24 hours after the treatment: no
change in expression pattern was seen
(magnification x 45).
PDGF-B transcript was elevated significantly at the end of the
observation period. The mRNA level of the other growth
facors investigated did not change. No evidence for a partici-
pation of EGF or IGF-I of renal origin in the proliferative
response after toxic proximal tubular necrosis was found so far.
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